UBS Group AG Ceases to Be Substantial Holder in Artrya Limited on 6 November 2026

Shwetambri Chauhan

10 November 2026 06:25 PM AEDT

UBS Group AG Ceases to Be Substantial Holder in Artrya Limited on 6 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Artrya Limited (ASX:AYA) has received formal notification that UBS Group AG and its related bodies corporate ceased to be a substantial holder in the company on 6 November 2026, according to a Form 605 filing lodged with the exchange on 10 November 2026.

Key Points

UBS Group AG and its related bodies corporate ceased to be a substantial holder in Artrya Limited on 6 November 2026.
The notice was signed by Ruby Ko, authorised signatory, and dated 10 November 2026.
The previous substantial holding notice was given to the company on 9 November 2026 and was dated 5 November 2026.
Changes on 6 November 2026 involved buy and sell transactions by UBS Securities Australia Ltd, as well as rehypothecated position movements by UBS AG London Branch and returns of rehypothecated positions by UBS AG, Australia Branch.

Cessation of Substantial Holding in Artrya Limited

According to the Form 605 filing, UBS Group AG and its related bodies corporate formally ceased to hold a substantial interest in Artrya Limited (ACN 624 005 741) on 6 November 2026. The notice was submitted on 10 November 2026 and was signed by Ruby Ko in the capacity of authorised signatory. The filing notes that the previous substantial holder notice had been given to the company on 9 November 2026, with that notice dated 5 November 2026. No changes in association with other parties were disclosed in the filing.

Transaction Details on 6 November 2026

Appendix A of the filing sets out the specific changes in relevant interests on 6 November 2026. UBS Securities Australia Ltd conducted multiple buy and sell transactions in Artrya ordinary shares on that date. Buy transactions included parcels of 18,564, 6,024, 683, 92, 26,555, 40,037, 82,113, 2,196, 1,999, 156,353, and other ordinary shares. Sell transactions included parcels of 78,251, 161,778, 16,189, 38,438, 25,488, and 4,702 ordinary shares, among others. All transactions were in ordinary shares of Artrya Limited.

Rehypothecated Position Movements by UBS AG Entities

The filing also discloses movements in rehypothecated positions on 6 November 2026. UBS AG London Branch recorded a rehypothecated position of 43,000 ordinary shares, with no consideration stated. UBS AG, Australia Branch recorded multiple returns of rehypothecated positions across ordinary shares, with individual parcels ranging from 1,011 to 739,350 shares. The consideration for all rehypothecated and returned rehypothecated position transactions was listed as not applicable in the filing. No associates were identified as having changed their nature of association in connection with this notice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.